T

Telomir Pharmaceuticals Inc
NASDAQ:TELO

Watchlist Manager
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Watchlist
Price: 4.27 USD -0.7%
Market Cap: 126.4m USD
Have any thoughts about
Telomir Pharmaceuticals Inc?
Write Note

Telomir Pharmaceuticals Inc
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Telomir Pharmaceuticals Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
T
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Other Current Assets
$304k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Other Current Assets
$4.2B
CAGR 3-Years
5%
CAGR 5-Years
12%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Other Current Assets
$1.8B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
-2%
Pfizer Inc
NYSE:PFE
Other Current Assets
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
-9%
CAGR 10-Years
-5%
Merck & Co Inc
NYSE:MRK
Other Current Assets
$7.4B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
-1%
Eli Lilly and Co
NYSE:LLY
Other Current Assets
$8.4B
CAGR 3-Years
40%
CAGR 5-Years
29%
CAGR 10-Years
26%
No Stocks Found

Telomir Pharmaceuticals Inc
Glance View

Market Cap
126.4m USD
Industry
Pharmaceuticals

Telomir Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2024-02-09. Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The firm is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.

TELO Intrinsic Value
1.47 USD
Overvaluation 66%
Intrinsic Value
Price
T

See Also

What is Telomir Pharmaceuticals Inc's Other Current Assets?
Other Current Assets
304k USD

Based on the financial report for Dec 31, 2023, Telomir Pharmaceuticals Inc's Other Current Assets amounts to 304k USD.

What is Telomir Pharmaceuticals Inc's Other Current Assets growth rate?
Other Current Assets CAGR 1Y
543%

Over the last year, the Other Current Assets growth was 543%.

Back to Top